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Abstract
Background: Age-associated decline in testosterone levels represent one of the potential mechanisms involved in the
development of frailty. Although this association has been widely reported in older men, very few data are available in
women. We studied the association between testosterone and frailty in women and assessed sex differences in this
relationship.
Methods: We used cross-sectional data from the Toledo Study for Healthy Aging, a population-based cohort study of
Spanish elderly. Frailty was defined according to Fried’s approach. Multivariate odds-ratios (OR) and 95% confidence
intervals (CI) associated with total (TT) and free testosterone (FT) levels were estimated using polytomous logistic
regression.
Results: In women, there was a U-shaped relationship between FT levels and frailty (p for FT
2=0.03). In addition, very low
levels of FT were observed in women with $4 frailty criteria (age-adjusted geometric means=0.13 versus 0.37 in subjects
with ,4 components, p=0.010). The association of FT with frailty appeared confined to obese women (p-value for
interaction=0.05).In men, the risk of frailty levels linearly decreased with testosterone (adjusted OR for frailty=2.9 (95%CI,
1.6–5.1) and 1.6 (95%CI, 1.0–2.5), for 1 SD decrease in TT and FT, respectively). TT and FT showed association with most of
frailty criteria. No interaction was found with BMI.
Conclusion: There is a relationship between circulating levels of FT and frailty in older women. This relation seems to be
modulated by BMI. The relevance and the nature of the association of FT levels and frailty are sex-specific, suggesting that
different biological mechanisms may be involved.
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Introduction
In the last decades the concept of frailty has emerged as one of
the main conditions preceding the development of disability. Fried
et al. have given the most widely used definition of frailty [1]:
‘‘frailty is an age-associated syndrome characterized by a reduced
functional reserve and impaired adaptive capacity’’. This pheno-
type of frailty has shown a strong association with increased risks of
disability and other adverse outcomes: institutionalization, hospi-
talization, falls, and mortality [2,3,4].
This characterization of frailty stems from a physiological
framework where sarcopenia and muscle performance play a
pivotal role [5,6]. The contribution of different components to the
development of frailty (hormones, inflammation, oxidative stress,
mithochondrial DNA, etc) has been largely controversial since its
description [7]. Among hormones, low levels of endogenous
testosterone, largely linked to the amount and quality of muscle
mass, is one of the potential mechanisms involved in the
development of frailty [8,9]. Although the age-associated decline
in testosterone occurs both in men and women [8,10], this decline
does not arise to the same extent in both sexes, suggesting a
possible differential impact on frailty according to sex. To date, a
consistent number of studies have reported an association between
low testosterone levels and frailty in men [11,12,13]. However,
although women represent around 2/3 of individuals with frailty,
little is known on the impact of low testosterone on frailty or its
components in women. To our knowledge, only two recent cross-
sectional studies have examined this issue in post-menopausal
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32401women; while Cappola et al. [14] did not find free testosterone
(FT) to be related to frailty, Wu et al. [12] reported an inverse
association of TT (total testosterone) and FT with frailty in a small
sample of Asian individuals.
In this context, using data from a population-based cohort of
Spanish elders, we aimed to evaluate the sex-specific association
between testosterone (total and free) and frailty.
Methods
Ethic statements
All study participants gave a signed informed consent. If a
participant was not able to consent, his caregiver (member of his
family or legal tutor) consented on his behalf. The study protocol
was approved by the Clinical Research Ethics Committee of the
Complejo Hospitalario de Toledo, Spain.
Study population
This analysis is based on the baseline data of the Toledo Study
for Healthy Aging (TSHA), a Spanish longitudinal population-
based cohort aimed at studying the determinants of frailty in older
adults. The study methods have been reported elsewhere [15].
Briefly, the TSHA comprises two cohorts population. The first
cohort is formed by the survivors of the ‘‘old cohort’’ called Toledo
Study (a population-based cohort initiated in 1994); a population
of men and women aged $77 years old in 2006 [16]. The second
cohort is formed by individuals aged between 65 and 76 years-old
specifically recruited for this study in 2006 (Figure 1). In both
studies, subjects were selected by a two-stage random sampling
from the Municipal Census of the province of Toledo. Of the
previously existing Toledo Study 1,560 subjects were found to be
eligible. Regarding the new cohort, 3,676 were initially selected.
From these 5,236 individuals, and after exclusion of subjects who
died, who moved from Toledo, refused to participate or could not
be contacted, 2,488 subjects were included in the TSHA. This
final sample showed similar demographic characteristics than the
original sample. Of note, subjects selected from the ‘‘old cohort’’
received the same baseline assessment than subjects newly
selected.
At baseline, data were collected by trained psychologists at the
subjects’ house. Questionnaires included socio-demographic
characteristics, social support, limitations in activities of daily
living (Katz index [17] and Lawton index [18]), health-related
quality of life, physical activity, diet, alcohol use, and depressive
symptoms and an extensive neuropsychology evaluation.
Study participants also underwent a physical exam performed
by nurses specifically trained for the purpose of this study. Heart
rate, blood pressure, anthropometric variables and the ankle-
brachial index were measured. In addition, electrocardiogram,
spirometry, and physical performance tests (upper and lower
extremity strength, walk speed, balance and sit and stand from
chair test) were performed. Information on comorbidity were self-
reported, and include cardiovascular disease, hypertension,
diabetes mellitus, high cholesterol, cancer, and dementia.
Hormones measures
At baseline, all participants were invited to be drawn a sample
of blood (45cc) while fasting. Samples were centrifuged and serum
fraction taken to the laboratory within two hours, using containers
at a temperature between 2 and 4uC, and then divided in aliquots
and stored at 280uC. Serum concentration of TT and FT were
measured in the laboratory of the Department of Biochemistry of
the Hospital Universitario de Getafe (Madrid, Spain) using
enzyme immunoassay techniques (ELISA) (DRG Testosterone,
DRG Free Testosterone ELISA kits) in a DYNEX DS2
Automated ELISA System. Analytical sensitivity and intra- and
interassay reagents ‘coefficient of variation were respectively: TT
ELISA: 0.083 ng/ml; 3.34–4.16% and 4.73–9.94%; FT ELISA:
0.06 pg/ml; ,10% and ,10%. Values of TT and FT lower than
the sensitivity threshold were given the value of this threshold in
statistical analysis.
Frailty measure
Frailty was defined, according to Fried’s et al. approach [1], as
the presence of three or more of the following components:
slowness, weakness, weight loss, exhaustion, and low physical
activity. Otherwise, subjects were classified as non-frail if no
component were present, and as pre-frail if they had one or two of
them. The components’ definition has been described elsewhere
[15]. Briefly, weight loss was defined as an unintentional loss of at
least 4.5 kg during the last year, slowness was defined using the
three-meter walking speed test, adjusted for sex and height
according to the standards of the Short Physical Performance
Battery [19]. To assess weakness, strength was measured with a
Jaymar hydraulic dynamometer, according to the standards of the
Hispanic EPESE [20]. Exhaustion was assessed using two
questions (‘‘I felt that anything I did was a big effort’’ and ‘‘I felt
that I could not keep on doing things’’ at least 3 to 4 days a week’’)
of the Center for Epidemiological Studies Depression Scale [21].
Finally, low physical activity was defined as the worse quintile in
the PASE scores [22].
Among the 1,972 subjects with a physical examination, 330
could not perform the physical performance test battery due to
poor health and were excluded (Figure 1). As fully described in
Garcia-Garcia et al. [15], the 1,972 subjects with physical
examination were not different from the total TSHA cohort in
terms of socio-demographic characteristics and comorbidities.
Statistical analysis
Differences in testosterone levels according to subject’s charac-
teristics were assessed using Student t-test or ANOVA test. In case
of non-normality, TT and FT variables were log-transformed.
Levels of TT and FT according to frailty status are expressed as
age-adjusted geometric means (GM) and inter quartile range
(IQR). Main study associations were summarized with odds-ratios
(OR) of pre-frailty and frailty per 1 SD decrease in testosterone.
Age and multivariate-adjusted OR and 95% confidence intervals
(CI) were estimated from polytomous logistic regression. Adjust-
ment included age, body mass index (BMI), education, hyperten-
sion, hypercholesterolemia, diabetes, and history of myocardial
infarction or stroke. Because of the potential role of adipose tissue
in the pathophysiological pathways leading to frailty, we seek for
interaction of TT and FT with BMI on frailty. Finally, we display
age-adjusted GM, IQR values of TT and FT according to each
component of frailty and to the number of components. The
association between each component of frailty and, TT and FT
was assessed using age-adjusted logistic regression. ANOVA was
used to compare the GM of TT and FT according to the number
of components.
To examine for departure from linearity, analyses were run
according to quartiles of hormones. Standard tests for linear trend
and deviation from linearity were performed. We also tested
quadratic terms for TT and FT to evaluate a possible U- or J-
shaped relationship with frailty.
Analyses were conducted in each sex separately. Statistical
significance was set at 2-sided p#0.05. All analyses were
performed using SAS statistical software version 9.2.
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Study population
From the 1,642 subjects where frailty was determined, 1,287
also had a measure of testosterone (552 were men and 735
women). Subjects without blood sample were not different from
the others in terms of age, sex, and comorbidities [15]. The mean
age of our study sample was 74.4. and 47.5% of the subjects had at
least two cardiovascular risk factors. In addition, 9.1% had
reported a previous myocardial infarction or stroke.
TT and FT according to socio-demographic and medical
variables
The median TT and FT values were 4.31 ng/ml and 6.05 pg/
ml respectively in men, and 0.43 ng/ml and 0.38 pg/ml,
respectively in women. The range and distribution of the data
were different by sex (table 1).
Table 1 also displays the mean levels of TT and FT according to
socio-demographic and medical characteristics in men and women
separately. In men, TT decreased with age, obesity, hypercholes-
terolemia, and history of myocardial infarction. FT decreased with
Figure 1. Flow Chart of the Study Sample Selection.
doi:10.1371/journal.pone.0032401.g001
Sex, Testosterone and Frailty in the Elderly
PLoS ONE | www.plosone.org 3 March 2012 | Volume 7 | Issue 3 | e32401age and hypercholesterolemia. In women, TT and FT decreased
with age but statistical significance was not reached (p=0.148 and
p=0.215, respectively). Low levels of TT were associated with
hypercholesterolemia (p=0.049). FT was significantly associated
with none of the characteristics studied but lower levels of FT were
observed in subjects with a BMI,25 kg/m
2 (p=0.173) or with a
history of stroke (p=0.105).
Association of TT and FT with frailty
Overall, 42.1% of the subjects were pre-frail and 8.3% frail.
Although sex differences did not reach statistical significance
(p=0.114), we noted 6.5% of frail subjects in men versus 9.7% in
women (table 2).
In men, TT decreased across frailty severity (table 2).
Compared with non-frail, for 1 SD decrease in TT, the age-
adjusted OR of being pre-frail was 1.35 times higher (95%CI,
1.08–1.70) and the OR of being frail was 1.79 times higher (95%
CI, 1.31–2.44) (table 3). Results did not change significantly after
adjustment for all socio-demographic characteristics and comor-
bidities. Frailty was also inversely associated with FT (age-adjusted
OR=1.59, 95% CI 1.18–2.15). The OR of being frail linearly
decreased across quartiles of TT and FT (p for linear trend 0.005
and 0.037, respectively). No significant interactions was observed
between TT, FT and BMI on frailty (p=0.602 and 0.193,
respectively).
In women, FT was lower in frail subjects compared with non-
frail or pre-frail but the association did not reach statistical
significance (p=0.196, table 2). When FT was classified into
quartiles, deviation from linearity was observed (p=0.009) and
results suggested a U-shaped relationship between FT and frailty
(p for FT
2=0.029, table 4). Compared with non-frail, the risk of
being frail was 2.69 times higher (95%CI 1.07–6.78) in women
with the highest FT values and more than 3 times higher (95%CI
1.38–8.24) in women with the lowest FT values. No association
was found between TT and frailty in women. Finally, we found
evidence of an interaction between FT and obesity on frailty
(Figure 2). The U-shaped relationship between FT and frailty was
confined to women with obesity (p for interaction=0.050).
Table 1. Means (standard deviation) of Total and Free Testosterone according to Subject’s Sociodemographic and Medical
Characteristics, by Sex.
Men Women
TT, ng/ml FT, pg/ml TT, ng/ml FT, pg/ml
n m SD p-value* m SD p-value* n m SD p-value* m SD p-value*
Quartiles 1 138 2.28 1.07 2.30 1.28 183 0.16 0.05 0.07 0.02
Testosterone 2 138 3.89 0.27 5.08 0.65 184 0.33 0.05 0.23 0.08
3 138 5.01 0.42 7.52 0.83 184 0.53 0.07 0.60 0.16
4 138 7.26 1.45 14.9 7.83 183 1.14 1.06 2.43 2.22
Age ,75 293 4.73 2.17 0.029 7.84 6.62 0.005 391 0.57 0.78 0.148 0.91 1.65 0.215
[75–80[ 172 4.52 1.78 6.73 5.00 225 0.53 0.39 0.78 1.25
$80 87 4.39 2.06 7.52 6.49 118 0.47 0.57 0.69 1.11
BMI in class ,25 94 4.87 2.46 0.009 8.09 7.33 0.948 98 0.54 0.69 0.944 0.76 1.53 0.173
[25–30[ 276 4.83 1.99 7.17 4.78 280 0.56 0.71 0.83 1.47
$30 181 4.15 1.79 7.50 7.25 349 0.53 0.59 0.87 1.44
Educational level No formal schooling 374 4.56 2.05 0.696 7.67 6.69 0.835 485 0.52 0.48 0.376 0.84 1.41 0.881
Uncompleted school 77 4.75 2.20 7.31 5.25 148 0.55 0.86 0.80 1.54
Primary or secondary
school
100 4.68 1.88 6.71 4.45 99 0.63 0.95 0.84 1.57
Hypertension No 296 4.71 2.13 0.238 7.55 6.68 0.581 313 0.57 0.73 0.468 0.92 1.77 0.92
Yes 249 4.50 1.95 7.32 5.53 415 0.52 0.58 0.78 1.18
Hypercholesterolemia No 371 4.79 2.10 0.005 7.95 6.96 0.039 395 0.60 0.82 0.049 0.91 1.50 0.113
Yes 164 4.25 1.87 6.42 3.90 326 0.47 0.36 0.75 1.43
Diabetes No 434 4.69 2.08 0.069 7.56 6.51 0.844 596 0.55 0.71 0.654 0.79 1.42 0.216
Yes 109 4.29 1.89 7.08 4.69 131 0.48 0.26 1.04 1.64
Myocardial infarction No 495 4.70 2.05 0.001 7.59 6.25 0.061 704 0.54 0.65 0.658 0.84 1.48 0.665
Yes 54 3.75 1.62 6.15 5.16 27 0.60 0.64 0.69 0.98
Stroke No 527 4.63 2.03 0.301 7.43 6.06 0.938 708 0.54 0.64 0.084 0.85 1.47 0.105
Yes 23 4.19 1.91 8.18 8.07 22 0.54 1.02 0.63 1.20
Dependance to BADL No 487 4.65 2.06 0.149 7.49 6.30 0.684 579 0.54 0.65 0.173 0.83 1.51 0.328
Yes 60 4.25 1.78 6.89 4.80 147 0.50 0.53 0.84 1.19
Dependance to IADL No 100 4.78 1.77 0.270 7.90 5.01 0.199 401 0.48 0.29 0.956 0.74 1.09 0.452
Yes 385 4.53 2.04 7.22 6.27 314 0.58 0.83 0.93 1.77
*p-value are calculated from Student t-test or from ANOVA when the covariate had more than 2 categories, Significant differences are highlighted in bold.
doi:10.1371/journal.pone.0032401.t001
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In men, taking into account age, all components of frailty were
associated with lower levels of TT and, low physical activity,
weakness and weight loss with lower levels of FT (Table 5). In
women, lower levels of TT and FT were observed in individuals
presenting each component of frailty (except for weight loss where
TT is slightly higher), but none of the age-adjusted associations
was significant (table 6). Table 5 shows a smooth linear decline in
TT and FT with the number of frailty components in men (age-
adjusted p,0.0001 and p=0.002, respectively) whereas only very
low concentrations of FT were observed in women presenting
more than 4 components (age-adjusted GM=0.13 versus 0.37 in
subjects with less than 4 components; age-adjusted p for
ANOVA=0.010, p for difference between women presenting
more than 4 components and each one of the other categories was
,0.001, table 6).
Sensitivity analysis
We performed a sensitivity analysis excluding all men taking a
treatment for prostate cancer or adenoma (n=62). Although these
men had slightly higher means of TT (5.0 (3.7) versus 4.6 (3.4), p-
value=0.172) and FT (9.8 (5.1) versus 7.1 (3.9), p=0.039),
univariate and multivariate analysis regarding the association of
TT and FT with frailty were not modified (data not shown). No
women were using hormonal therapy in our study.
Discussion
In a large sample of Spanish community dwellers, we found, for
the first time in a Caucasian population, a significant U-shaped
relationship between circulating levels of FT and frailty in older
women. In addition, we highlighted different patterns of
association of FT with frailty and its components according to sex.
Table 2. Age-adjusted Geometric Means (GM)*, Inter Quartile Range (IQR) of Total and Free Testosterone Concentration according
to Frailty Status, by Sex.
Men Women
TT, ng/ml FT, pg/ml TT, ng/ml FT, pg/ml
n (%) GM, IQR GM, IQR n (%) GM, IQR GM, IQR
Non frail 275 (49.8) 4.43 (3.56–5.98) 5.92 (4.43–9.48) 363 (49.5) 0.41 (0.23–0.68) 0.37 (0.13–0.93)
Prefrail 241 (43.7) 3.70 (3.35–5.69) 5.00 (3.63–9.20) 300 (40.9) 0.40 (0.25–0.67) 0.37 (0.12–0.94)
Frail 36 ( 6.5) 2.45 (1.82–4.71) 2.80 (1.97–7.61) 71 ( 9.7) 0.36 (0.16–0.56) 0.27 (0.06–0.88)
p-value ,0.0001 0.003 0.474 0.196
*Age-adjusted GM were calculated using linear regression.
doi:10.1371/journal.pone.0032401.t002
Table 3. Relationship between Frailty Status and Total and Free Testosterone Concentration, in Men.
Pre-frail (n=241) Frail (n=36)
n (%) OR (95%CI) p-value n (%) OR (95%CI) p-value
TT, ng/ml, OR for 1 SD decrease
Age adjusted 1.35 (1.08–1.70) 0.008 1.79 (1.31–2.44) 0.0002
Mutivariate adjusted1 1.27 (1.00–1.62) 0.042 1.85 (1.31–2.62) 0.0004
OR for quartiles1
Q1 63 (45.7) 1.32 (0.77–2.25) 0.320 18 (14.5) 3.01 (0.98–9.29) 0.055
Q2 63 (45.7) 1.34 (0.79–2.27) 0.272 8 (5.5) 2.15 (0.63–7.37) 0.221
Q3 58 (42.0) 1.07 (0.64–1.81) 0.795 3 (2.2) 0.25 (0.04–1.45) 0.121
Q4 57 (41.3) 1.00 7 (4.8) 1.00
p for trend 0.225 0.005
FT, pg/ml, OR for 1 SD decrease
Age adjusted 1.17 (0.96–1.43) 0.108 1.59 (1.18–2.15) 0.002
Mutivariate adjusted{ 1.14 (0.93–1.41) 0.191 1.67 (1.22–2.30) 0.001
OR for quartiles1
Q1 67 (48.6) 1.32 (0.78–2.23) 0.307 15 (11.3) 5.66 (1.41–22.8) 0.015
Q2 57 (41.3) 0.85 (0.50–1.41) 0.521 6 ( 4.4) 1.68 (0.37–7.70) 0.505
Q3 56 (40.6) 0.93 (0.55–1.56) 0.785 11 ( 7.8) 3.32 (0.80–13.9) 0.100
Q4 61 (44.2) 1.00 4 ( 2.9) 1.00
p for trend 0.427 0.037
Results from Polytomous Regression Analyses.
1Adjusted for age, body mass index, educational level, hypertension, hypercholesterolemia, diabetes, history of myocardial infarction and stroke.
Significant differences are highlighted in bold.
doi:10.1371/journal.pone.0032401.t003
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men. This result confirms those from other observational studies.
Indeed, several studies have found a cross-sectional association
between low levels of bioavailable or FT and frailty or the severity
of its components [11,12,23,24,25]. Regarding TT, results are less
consistent across studies, some of them suggesting an association
[12,23,25] and other not [11,13,24]. Furthermore, we found a
strong association between each component of frailty and TT in
Figure 2. Multivariate Odds Ratios and 95% Confidence Interval of Frailty Associated with Quartiles of Free Testosterone, by
Obesity, in Women. Part A corresponds to women with BMI,30 kg/m
2. Part B corresponds to women with BMI$30 kg/m
2. ORs are adjusted for
age, body mass index, educational level, hypertension, hypercholesterolemia, diabetes, history of myocardial infarction and stroke. Age-adjusted p-
value for interaction between BMI ($30 kg/m
2) and FT
2=0.050.
doi:10.1371/journal.pone.0032401.g002
Table 4. Relationship between Frailty Status and Total and Free Testosterone Concentration, in Women.
Pre-frail (n=300) Frail (n=71)
n (%) OR* (95%CI) p-value n (%) OR* (95%CI) p-value
TT, ng/ml, OR for 1 SD decrease
Age adjusted 1.02 (0.50–1.19) 0.772 1.15 (0.88–1.50) 0.297
Mutivariate adjusted1 1.00 (0.85–1.17) 0.968 1.13 (0.85–1.50) 0.378
OR for quartiles1
Q1 68 (37.2) 0.82 (0.51–1.31) 0.496 23 (12.3) 1.50 (0.66–3.44) 0.334
Q2 88 (47.8) 1.41 (0.40–2.22) 0.156 14 ( 7.8) 1.14 (0.46–2.83) 0.185
Q3 67 (36.4) 0.83 (0.52–1.32) 0.480 22 (11.9) 1.46 (0.63–3.38) 0.380
Q4 77 (42.1) 1.00 12 ( 6.6) 1.00
p U-shaped 0.948 0.066
FT, pg/ml, OR for 1 SD decrease
Age adjusted 1.00 (0.85–1.10) 0.925 1.27 (0.96–1.68) 0.091
Mutivariate adjusted1 1.00 (0.91–1.10) 0.905 1.22 (0.91–1.63) 0.180
OR for quartiles1
Q1 69 (37.7) 1.15 (0.72–1.84) 0.552 27 (15.1) 3.37 (1.38–8.24) 0.008
Q2 82 (44.8) 1.60 (1.01–2.54) 0.044 17 ( 9.6) 2.65 (1.05–6.78) 0.042
Q3 73 (39.7) 1.00 10 ( 5.2) 1.00
Q4 75 (41.0) 1.27 (0.80–2.00) 0.308 17 ( 9.1) 2.69 (1.07–6.78) 0.036
p U-shaped 0.619 0.029
Results from Polytomous Regression Analyses.
1Adjusted for age, body mass index, educational level, hypertension, hypercholesterolemia, diabetes, history of myocardial infarction and stroke.
Significant differences are highlighted in bold.
doi:10.1371/journal.pone.0032401.t004
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associated with decreased FT. These results are consistent with
other studies reporting association of TT and FT with muscle
strength [11,13,23,24,25], walking speed [11,24], and weight loss
[23].
We also report a U-shaped relationship between FT and frailty
in women. Higher and lower levels of FT were associated with an
increased probability of being frail. This result is different from the
one from Cappola et al. [14] which suggested a possible (but not
significant) linear association between decreasing testosterone and
frailty.
Interestingly, we found various differences in the relationship
between testosterone and frailty according to sex. Firstly, we
showed that the probability of frailty linearly increased with
testosterone’s decline in men, while this relationship was U-shaped
in women. Secondly, analyses regarding the components of frailty
Table 5. Age-adjusted GM*, IQR value of total and free testosterone according to components and number of components of
frailty, in Men.
TT, ng/ml TL. pg/ml
N GM IQR p-value1 N GM IQR p-value1
Non-frail 275 4.39 (3.56–5.98) Ref 275 5.93 (4.48–9.48) Ref
Exhaution 26 2.86 (2.88–4.05) ,0.001 26 4.31 (3.06–8.08) 0.090
Low physical activity 145 3.42 (3.03–5.41) 0.002 145 4.57 (3.63–8.41) 0.029
Weakness 102 2.89 (2.85–5.00) ,0.0001 102 3.71 (2.77–8.16) 0.0005
Slowness 126 3.42 (3.32–5.52) 0.007 126 4.81 (3.81–9.11) 0.079
Weight loss 39 3.16 (2.88–5.92) 0.001 39 3.67 (2.24–8.84) 0.004
Nb of components N GM IQR p-value# N GM IQR p-value#
0 275 4.39 (3.56–5.98) ,0.0001 275 5.93 (4.48–9.48) 0.002
1 161 4.06 (3.59–5.81) 161 5.37 (3.97–9.11)
2 80 3.16 (3.12–5.25) 80 2.75 (3.25–9.20)
3 29 2.56 (2.13–4.57) 29 2.51 (1.73–7.53)
4o r5 7 2.34 (0.79–5.81) 7 5.87 (2.88–8.49)
*Age-adjusted GM were calculated using linear regression.
1Age-adjusted p-value were calculated using logistic regression.
#Age-adjusted p-value were calculated using ANOVA.
Significant differences are highlighted in bold.
doi:10.1371/journal.pone.0032401.t005
Table 6. Age-adjusted GM*, IQR value of total and free testosterone according to components and number of components of
frailty, in Women.
TT, ng/ml TL. pg/ml
N GM IQR p-value1 N GM IQR p-value1
Non-frail 363 0.41 (0.23–0.68) Ref 363 0.37 (0.13–0.98) Ref
Exhaution 130 0.40 (0.29–0.62) 0.830 129 0.30 (0.08–0.86) 0.100
Low physical activity 82 0.41 (0.19–0.62) 0.964 82 0.36 (0.06–1.00) 0.941
Weakness 146 0.35 (0.22–0.58) 0.059 146 0.32 (0.09–0.88) 0.311
Slowness 178 0.36 (0.20–0.61) 0.076 176 0.32 (0.09–0.95) 0.187
Weight loss 84 0.43 (0.28–0.68) 0.523 84 0.35 (0.14–0.79) 0.740
Nb of components N GM IQR p-value# N GM IQR p-value#
0 363 0.41 (0.23–0.68) 0.470 363 0.37 (0.13–0.98) 0.010
1 218 0.39 (0.23–0.65) 219 0.36 (0.12–0.87)
2 82 0.41 (0.28–0.71) 80 0.40 (0.13–1.11)
3 50 0.39 (0.18–0.61) 50 0.37 (0.08–1.07)
4/5 21 0.30 (0.16–0.53) 21 0.13 (0.06–0.22)
*Age-adjusted GM were calculated using linear regression.
1Age-adjusted p-value were calculated using logistic regression.
#Age-adjusted p-value were calculated using ANOVA.
Significant differences are highlighted in bold.
doi:10.1371/journal.pone.0032401.t006
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men whereas, in women, no single component was associated
neither with TT nor with FT. Thirdly, while FT levels
progressively decrease with the number of frailty criteria in men,
they sharply decreased in women with 4 or 5 criteria. Finally,
obesity modified the effect of FT on frailty in women but not in
men.
The implication of testosterone in body-mass regulation, muscle
function and growth and, regulation of bone mineral density
[25,26,27,28] gives biological support to the relation between
testosterone decline and frailty. Additionally, testosterone may be
linked to weight loss through its effect on appetite [29]. However,
the mechanisms underlying sex differences and, the association of
higher levels of FT with frailty in women are not clear and need to
be explored in other studies. One explanation for the disparity
between sexes could be the implication of different biological
mechanisms in the relation between testosterone and frailty. While
testosterone plays a prominent role in frailty in old men, its role in
women, although present, seems less relevant. Other hormonal
axes and mediators may be of major importance in the relation
between testosterone and frailty in women. This is supported by
data from the Women’s Health and Aging Study where a multiple
hormonal burden was found to be more strongly associated with
frailty than the type of hormonal deficiency [14]. Moreover, if
testosterone plays a crucial role in men health, estrogens are the
most important sex-hormones in women. Considering that the
main source of estradiol in post-menopausal women comes from
the conversion of testosterone by aromatase in adipose tissue, and
that estrogen therapy and endogenous estrogen have been
suggested to respectively have a positive effect on muscle strength
[30,31] and on bone mineral density [32], we can hypothesized
that estradiol may play a substantial role in the relation between
FT and frailty in women. Our results regarding the interaction
between FT and obesity in women but not in men reinforce this
hypothesis as they suggest a more important role of the estrogenic
climate in women than men.
The strengths of our study mainly pertain to our large sample
size of randomly selected community dwellers and to the well
validated criteria used for the definition of frailty. In addition,
although FT is considered the more biologically active hormone,
nearly none of the previous studies have investigated the true
amount of FT but used a calculated estimation. Even if the
methods used to calculate free testosterone are recognized reliable
[33], we cannot exclude that it could explain the difference
between our study and others’. Nonetheless, the method used to
measure testosterone also represents our main limitation. Indeed,
levels of testosterone are very low in postmenopausal women, and
thus the use of a highly sensitive assay may have been more
appropriate. However, as all value of FT under the detection
threshold were set to this threshold value, we are more likely to
underestimate the true association between low levels of FT with
frailty. In addition, when removing all women with a value of FT
under the threshold of detection from the analyses (n=132), the
result remains similar (data not shown). Other important limitation
is the observational and transversal characteristics of our study
which do not allow us to conclude in terms of causality. Finally,
although we adjusted our analyses for many confounding factors,
we cannot exclude that the finding of a U-shaped relationship
between FT and frailty may be the results of unmeasured
confusion.
To conclude, our results show, for the first time, an implication
of testosterone in the frailty syndrome in women, confirm the
association of testosterone with frailty in men, and suggest a
differential association of testosterone with frailty by sex. In light of
the recent findings regarding the benefit of testosterone supple-
mentation on the various component of frailty, our data, if
confirmed, may have clinical implication. Indeed, most, if not all,
clinical trials suggesting that maintaining testosterone in a normal
range may contribute to prevent frailty have been performed in
men with hypogonadism [28,34,35,36,37]. Here, we suggest that
even without hypogonadism, men with low levels of testosterone
are at increased risk of physical frailty and could thus benefit from
testosterone therapy. In addition, postmenopausal women might
also benefit from testosterone administration in the context of a
wider hormonal care.
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